- Report of Foreign Issuer (6-K)
October 11 2012 - 5:08PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of
1934
For the month of October 2012
Commission File Number 001-35203
THERATECHNOLOGIES INC.
(Translation of registrants name into
English)
2310 Alfred-Nobel Boulevard Montréal, Québec, Canada H4S 2B4
(Address of principal executive offices)
Indicate by
check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F
¨
Form 40-F
x
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Yes
¨
No
x
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an
attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7):
Yes
¨
No
x
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a
Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the
registrants home country), or under the rules of the home country exchange on which the registrants securities are traded, as long as the report or other document is not a press release, is not required to be and has not been
distributed to the registrants security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
¨
No
x
If Yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):
82-
.
THERATECHNOLOGIES INC.
|
|
|
Exhibit
|
|
Description
|
|
|
99.1
|
|
Unaudited Interim Consolidated Financial Statements for the nine-month period ended August 31, 2012 and August 31, 2011
|
|
|
99.2
|
|
Managements Discussions and Analysis for the three-month and nine-month periods ended August 31, 2012
|
|
|
99.3
|
|
Press Release Dated October 11, 2012
|
|
|
99.4
|
|
Canadian Form 52-109F2 Certification of Interim Filings - CEO
|
|
|
99.5
|
|
Canadian Form 52-109F2 Certification of Interim Filings - CFO
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
THERATECHNOLOGIES INC.
|
|
|
By:
|
|
/s/ Luc Tanguay
|
Name:
|
|
Luc Tanguay
|
Title:
|
|
Senior Executive Vice President
and Chief Financial Officer
|
Date: October 11, 2012
Therasense (NASDAQ:THER)
Historical Stock Chart
From Jun 2024 to Jul 2024
Therasense (NASDAQ:THER)
Historical Stock Chart
From Jul 2023 to Jul 2024